Quantum BioPharma Ltd. (QNTM), Tuesday announced that the company has received the clinical study report for the phase 1 multiple ascending dose trial of experimental multiple sclerosis drug Lucid-MS dosing in healthy adult participants.
The announcement, made through the company's subsidiary, Huge Biopharma Australia Pty Ltd., noted that the report showed no safety or tolerability concerns among healthy participants following treatment with consecutive daily dosing of Lucid-MS.
The positive findings help the company to advance the clinical development of Lucid-MS as it is a critical component of the investigational new drug application with the FDA.
Additionally, the company is preparing for the launch of efficacy trials in patients with multiple sclerosis.
Currently, QNTM is trading at $27.13, down 2.41 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.